Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AstraZeneca Says US District Court Finds SEROQUEL XR Formulation Patent As Valid

AstraZeneca Plc (AZN: Quote,AZN.L) said Thursday that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR (quetiapine fumarate) extended release tablets to be valid.

According to the company, the court has ruled that Anchen Pharmaceuticals Inc., Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (MYL) have infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.

The decision follows a ruling made in the UK on March 22, 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on March 7, 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.

AstraZeneca said it is pleased with the US District Court's decision, which the company believes underlines the strength of its patents.

Seroquel generated $5.83 billion in global sales last year, with $1.4 billion coming from Seroquel XR.

Click here to receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State. While the Conference Board released a report on Friday showing a continued increase by its index of leading U.S. economic indicators in the month of August, the pace of growth showed a significant slowdown compared to the previous month.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.